Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genentech, Inc.
Jonsson Comprehensive Cancer Center
Adaptimmune
Innate Pharma
LG Chem
Incyte Corporation
Pfizer
Pfizer
MacroGenics
University of Virginia
Incyte Corporation
Checkpoint Therapeutics, Inc.
Molecular Templates, Inc.
Inhibrx Biosciences, Inc
RemeGen Co., Ltd.
Xencor, Inc.
Pliant Therapeutics, Inc.
University of California, San Francisco
University of Florida
Apexigen America, Inc.
Fate Therapeutics
Cantargia AB
Fate Therapeutics
Xencor, Inc.
Herlev Hospital
Advaxis, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
Genocea Biosciences, Inc.
Pfizer
Incyte Corporation
Shanghai Junshi Bioscience Co., Ltd.
Incyte Corporation